Please login to the form below

Not currently logged in
Email:
Password:

QMF149

This page shows the latest QMF149 news and features for those working in and with pharma, biotech and healthcare.

Novartis reveals full phase 3 results for Enerzair Breezhaler

Novartis reveals full phase 3 results for Enerzair Breezhaler

function compared to treatment with once-daily QMF149  (indacaterol acetate and mometasone furoate). ... The overall occurrence of adverse events and serious adverse events for both Enerzair Breezhaler and QMF149 in the study were generally low and

Latest news

  • Novartis strengthens case for its combination asthma drug Novartis strengthens case for its combination asthma drug

    The  asthma combination regimen, QMF149, is a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate. ... QMF149 also met the secondary endpoint of the study, demonstrating a statistically significant improvement in asthma

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics